Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Triple negative breast cancer

ECCO 15 - ESMO 34

20 - 24 Sep 2009

Published: 5 Nov 2009

Views: 14064

Rating:

Save

Dr Susanne Briest - University of Leipzig, Germany

Dr Susanne Briest from the University of Leipzig, Germany, interviewed at ECCO 15 - ESMO 34, Berlin, Sept 2009. Features of triple negative breast cancer and various cancers within the triple negative grouping. PARP inhibitors. Grouping tumours by similarity to BRCA 1- 'BRCAness'. Multidisciplinary teams. Speaking to managing editor Prof Gordon McVie.

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

CDK4/6 inhibitors added to first line show no greater benefit when compared to...

Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands

CDK4/6 inhibitors added to first line show no greater benefit when compared to their use in second line therapy in HR+, HER2- ABC ( Dr Gabe Sonke - Netherlands Cancer Institute, Amsterdam, Netherlands )

Prognostic value of HER2-low status in breast cancer: A systematic review and...

Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy

Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis ( Dr Chiara Molinelli - Università degli Studi di Genova, Genoa, Italy )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Loco-regional management after neoadjuvant chemotherapy

Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA

Loco-regional management after neoadjuvant chemotherapy ( Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA )

Personalised risk-stratified breast cancer screening for BRCA germline...

Prof Banu Arun - MD Anderson Cancer Center, Houston, USA

Personalised risk-stratified breast cancer screening for BRCA germline mutations and other genes ( Prof Banu Arun - MD Anderson Cancer Center, Houston, USA )

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC ( Dr Virginia Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

More from ecancer